A Randomized Thorough QT Trial Using Concentration‐QT Analysis to Evaluate the Effects of Centanafadine on Cardiac Repolarization
Clinical Pharmacology in Drug Development · 2025
DOI: 10.1002/cpdd.1545 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2025. Verfasst von Osman S Turkoglu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD, USA. Hauptthemen laut MEDLINE: Heart Rate. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Centanafadine is a norepinephrine/dopamine/serotonin reuptake inhibitor in development for treatment of attention‐deficit/hyperactivity disorder. This double‐blind, placebo‐ and moxifloxacin‐controlled, 3‐period crossover trial evaluated the effects of centanafadine (EB‐1020) and its metabolite (EB‐10601) on cardiac repolarization in 30 healthy adults (18‐65 years). Dosing sequences included centanafadine sustained‐release 800 mg (supratherapeutic) total daily dose, placebo, and moxifloxacin 400 mg. Electrocardiogram parameters and heart rate (HR) were assessed. The primary endpoint was placebo‐corrected change from baseline QTc (ΔΔQTc), analyzed using concentration‐QTc (C‐QTc) analysis. The C‐QTc slopes for centanafadine (−0.001 ms/[ng/mL]) and EB‐10601 (−0.0003 ms/[ng/mL]) were not statistically significant. Assay sensitivity was confirmed by the statistically significant C‐QTc slope for moxifloxacin (0.004 ms/[ng/mL]) and a 2‐sided 90% confidence interval lower bound >5 milliseconds. No change from baseline in QTcF or placebo‐corrected QTcF ≥10 milliseconds for centanafadine was observed at any postdose time point. No centanafadine‐treated participants had QTcF increases of >30 milliseconds and no relevant PR/QRS interval or HR increases were observed. The predicted ΔΔQTcF values of centanafadine, EB‐10601, and moxifloxacin at the geometric mean C max were −2.72, −1.59, and 11.75 milliseconds, respectively. No serious treatment‐emergent adverse events or deaths were reported. Centanafadine was generally safe and well‐tolerated, with no clinically meaningful effect on cardiac repolarization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD, USA.
Zitieren
APA
Turkoglu, O. S., Wang, X., Repella-Gordon, J., & Shoaf, S. E. (2025). A Randomized Thorough QT Trial Using Concentration‐QT Analysis to Evaluate the Effects of Centanafadine on Cardiac Repolarization. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1545
Vancouver
Turkoglu OS, Wang X, Repella-Gordon J, Shoaf SE. A Randomized Thorough QT Trial Using Concentration‐QT Analysis to Evaluate the Effects of Centanafadine on Cardiac Repolarization. Clinical Pharmacology in Drug Development. 2025. doi:10.1002/cpdd.1545
BibTeX
@article{Turkoglu2025,
author = {Turkoglu, Osman S and Wang, Xiaofeng and Repella-Gordon, Jennifer and Shoaf, Susan E},
title = {A Randomized Thorough QT Trial Using Concentration‐QT Analysis to Evaluate the Effects of Centanafadine on Cardiac Repolarization},
journal = {Clinical Pharmacology in Drug Development},
year = {2025},
doi = {10.1002/cpdd.1545}
}
EUVIMED